Analytical Data
-
Gene name
MRPL11
- Application
-
Alternative Names
MRPL11；Large ribosomal subunit Protein uL11m
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q9Y3B7
-
Expression Region
1-191aa
-
AA Sequence
MSKLGRAARGLRKPEVGGVIRAIVRAGLAMPGPPLGPVLGQRGVSINQFCKEFNERTKDIKEGIPLPTKILVKPDRTFEIKIGQPTVSYFLKAAAGIEKGARQTGKEVAGLVTLKHVYEIARIKAQDEAFALQDVPLSSVVRSIIGSARSLGIRVVKDLSSEELAAFQKERAIFLAAQKEADLAAQEEAAK
-
Molecular Weight
36.6 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
MRPL11, or Mitochondrial Ribosomal Protein L11, is a crucial component of the mitochondrial ribosome, participating in protein synthesis within mitochondria. It plays a significant role in translating mitochondrial mRNA into essential proteins that facilitate energy production and metabolic processes. Research on MRPL11 has gained momentum due to its implications in various diseases, particularly those associated with mitochondrial dysfunction. Abnormalities in mitochondrial protein synthesis can lead to a range of disorders, including neurodegenerative diseases and certain types of cancer. Furthermore, MRPL11 has been proposed as a potential biomarker for assessing disease progression and as a target for therapeutic interventions. The study of MRPL11 recombinant proteins allows researchers to understand its structural and functional characteristics better, paving the way for insights into mitochondrial biology and potential disease mechanisms. Through recombinant technology, scientists can produce large quantities of MRPL11 to investigate its interactions and roles in cellular pathways, thereby enhancing our understanding of mitochondrial dynamics and their implications for human health. This avenue of research holds promise for developing novel therapeutic strategies aimed at correcting mitochondrial dysfunction, with the potential for significant impact on treatments for related diseases.
